drugset

drugset / Trial / NCT05199337

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

NCT05199337 ↗

Phase 1/2 Completed 18 enrolled Zentalis Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis.

Timeline

Start: 2021-11-30
Primary completion: 2024-02-14
Completion: 2024-02-14

Publications

Locke M, Nieto M. AL Amyloidosis: Current Treatment and Outcomes. Adv Hematol. 2025 Mar 3;2025:7280805. doi: 10.1155/ah/7280805. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ZN-d5	Unknown	—	Oral

Indications